Michael Khan
Directeur Général chez Argonaute RNA Ltd.
Profil
Michael Khan is currently the Chief Executive Officer at Argonaute RNA Ltd.
He is also a member of Diabetes UK and HEART UK.
Previously, he was the Executive Director & Chief Medical Officer at Silence Therapeutics Plc from 2013 to 2016.
He also worked as the Head-Molecular Medicine & Associate Professor at the University of Warwick.
Dr. Khan holds a doctorate degree from University College London.
Postes actifs de Michael Khan
| Sociétés | Poste | Début |
|---|---|---|
| HEART UK | Corporate Officer/Principal | - |
| Diabetes UK | Corporate Officer/Principal | - |
Argonaute RNA Ltd.
 Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Directeur Général | 01/01/2021 |
Anciens postes connus de Michael Khan
| Sociétés | Poste | Fin |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Directeur Technique/Scientifique/R&D | 17/06/2016 |
| University of Warwick | Corporate Officer/Principal | - |
Formation de Michael Khan
| University College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Entreprise privées | 3 |
|---|---|
| Diabetes UK | |
| HEART UK | |
Argonaute RNA Ltd.
Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Commercial Services |